Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016141299 - METHODS FOR TREATING CANCER

Publication Number WO/2016/141299
Publication Date 09.09.2016
International Application No. PCT/US2016/020913
International Filing Date 04.03.2016
IPC
A61K 31/4375 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4375the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/501 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
501not condensed and containing further heterocyclic rings
CPC
A61K 31/501
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
50Pyridazines; Hydrogenated pyridazines
501not condensed and containing further heterocyclic rings
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/156
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
156Polymorphic or mutational markers
Applicants
  • CHILDREN'S HOSPITAL MEDICAL CENTER [US]/[US]
Inventors
  • DASGUPTA, Biplab
Agents
  • GUTTMAN, Harry J.
Priority Data
62/128,25604.03.2015US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR TREATING CANCER
(FR) MÉTHODES DE TRAITEMENT DU CANCER
Abstract
(EN)
Some embodiments of the invention include methods to treat cancer in animals by administering an SCD inhibitor. Other embodiments include treating cancer in animals where the SCD gene is absent in one or both chromatids by administering an SCD inhibitor. Still other embodiments include treating cancer in animals by administering an SCD inhibitor where the SCD gene is absent in one or both chromatids and the animal has a daily intake of one or more of (a) a specified amount of total fat, (b) a specified amount of total fatty acid, (c) a specified amount of total monounsaturated fatty acid, or (d) a specified amount of total oleic acid. Additional embodiments of the invention are also discussed herein.
(FR)
Certains modes de réalisation de l'invention comprennent des méthodes pour traiter le cancer chez l'animal par administration d'un inhibiteur de SCD. D'autres modes de réalisation comprennent le traitement du cancer chez des animaux chez lesquels le gène SCD est absent de l'un ou des deux chromatides par administration d'un inhibiteur de SCD. D'autres modes de réalisation additionnels comprennent le traitement du cancer chez des animaux par administration d'un inhibiteur de SCD dans le cas où le gène SCD est absent de l'un ou des deux chromatides et où l'animal a une prise journalière d'une ou de plusieurs de (a) une quantité spécifiée de graisse totale, (b) une quantité spécifiée d'acide gras totaux, (c) une quantité spécifiée d'acides gras mono-insaturés totaux, ou (d) une quantité spécifiée d'acide oléique total. L'invention concerne également des modes de réalisation supplémentaires.
Also published as
Latest bibliographic data on file with the International Bureau